Abbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday

Abbott Laboratories (NYSE:ABTGet Rating) will post its quarterly earnings results on Wednesday, January 25th.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $114.01 on Tuesday. The company has a current ratio of 1.86, a quick ratio of 1.43 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $108.56 and a 200-day moving average of $105.76. The firm has a market cap of $198.78 billion, a P/E ratio of 25.74, a P/E/G ratio of 5.05 and a beta of 0.69. Abbott Laboratories has a 1-year low of $93.25 and a 1-year high of $130.93.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be paid a $0.51 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.47. This represents a $2.04 dividend on an annualized basis and a yield of 1.79%. The ex-dividend date of this dividend is Thursday, January 12th. Abbott Laboratories’s dividend payout ratio is presently 46.05%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. BTIG Research decreased their price target on shares of Abbott Laboratories from $126.00 to $123.00 and set a “buy” rating for the company in a research note on Monday, October 17th. StockNews.com downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 20th. Jefferies Financial Group assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, October 12th. They issued a “hold” rating and a $110.00 price target for the company. Citigroup increased their price target on shares of Abbott Laboratories from $114.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Finally, Raymond James decreased their target price on shares of Abbott Laboratories from $117.00 to $109.00 and set an “outperform” rating for the company in a research note on Friday, October 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $125.06.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $97.46, for a total transaction of $4,873,000.00. Following the completion of the sale, the director now owns 6,873,500 shares of the company’s stock, valued at $669,891,310. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $97.46, for a total transaction of $4,873,000.00. Following the completion of the sale, the director now owns 6,873,500 shares of the company’s stock, valued at $669,891,310. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John F. Ginascol sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $112.32, for a total transaction of $1,235,520.00. Following the sale, the executive vice president now directly owns 111,912 shares of the company’s stock, valued at approximately $12,569,955.84. The disclosure for this sale can be found here. 0.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Worth Asset Management LLC purchased a new stake in Abbott Laboratories in the first quarter worth approximately $108,000. Fairfield Bush & CO. purchased a new stake in Abbott Laboratories in the first quarter worth approximately $131,000. Global Wealth Management Investment Advisory Inc. boosted its holdings in Abbott Laboratories by 16.5% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 1,249 shares of the healthcare product maker’s stock worth $148,000 after purchasing an additional 177 shares during the last quarter. BCK Partners Inc. purchased a new stake in Abbott Laboratories in the first quarter worth approximately $220,000. Finally, Eudaimonia Advisors LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth $240,000. Hedge funds and other institutional investors own 72.93% of the company’s stock.

Abbott Laboratories Company Profile

(Get Rating)

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.

Further Reading

Earnings History for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.